Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs

Clinical Drug Investigation

Volumn 31, Issue 5, 2011, Pages 351-355

  Mihovilovic, Karlo ^a   Ljubanovic, Danica ^b   Knotek, Mladen ^a  

^a University of Zagreb   (Croatia)

^b University of Zagreb   (Croatia)

Author keywords

Celecoxib; Cyclo oxygenase 2 inhibitors; Diclofenac; Meloxicam; Nephrotic syndrome; Nonsteroidal anti inflammatories; therapeutic use

Indexed keywords

ATORVASTATIN; BISOPROLOL; CELECOXIB; DICLOFENAC; LOSARTAN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE;

ADULT; ARTICLE; CASE REPORT; CAUCASIAN; DISEASE CONTROL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; HIP ARTHROPLASTY; HIP OSTEOARTHRITIS; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; IMMUNOFLUORESCENCE TEST; KIDNEY; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LABORATORY TEST; LEG EDEMA; MALE; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEINURIA; REMISSION; RISK FACTOR; TREATMENT DURATION; URINALYSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; HUMANS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; OSTEOARTHRITIS, HIP; PYRAZOLES; RECURRENCE; REMISSION INDUCTION; SULFONAMIDES; THIAZINES; THIAZOLES;

EID: 79953827610     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11586340-000000000-00000     Document Type: Article

References (23)

1. Hamza M, Dionne RA. Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. Curr Mol Pharmacol 2009; 2 (1): 1-14
2. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2006; 2 (2): 80-91 (Pubitemid 43355216)
3. Warren GV, Korbet SM, Schwartz MM, et al. Minimal change glomerulopathy associated with nonsteroidal anti-inflammatory drugs. Am J Kidney Dis 1989; 13 (2): 127-30 (Pubitemid 19063097)
4. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28 (1 Suppl. 1): S56-62 (Pubitemid 26234598)
5. Whelton A. Nephrotoxicity ofnonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106 (5B): 13S-24S (Pubitemid 29268660)
6. Almansori M, Kovithavongs T, Qarni MU. Cyclooxygenase-2 inhibitor-associated minimal-change disease. Clin Nephrol 2005; 63 (5): 381-4 (Pubitemid 40668232)
7. Alper Jr AB, Meleg-Smith S, Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 2002; 40 (5): 1086-90 (Pubitemid 35265490)
8. Brewster UC, Perazella MA. Acute tubulointerstitial nephritis associated with celecoxib. Nephrol Dial Transplant 2004; 19 (4): 1017-8 (Pubitemid 38455691)
9. Demke D, Zhao S, Arellano FM. Interstitial nephritis associated with celecoxib. Lancet 2001; 358 (9294): 1726-7
10. Esteve JB, Launay-Vacher V, Brocheriou I, et al. COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature. Clin Nephrol 2005; 63 (5): 385-9 (Pubitemid 40668233)
11. Henao J, Hisamuddin I, Nzerue CM, et al. Celecoxibinduced acute interstitial nephritis. Am J Kidney Dis 2002; 39 (6): 1313-7
12. Beun GD, Leunissen KM, Van Breda V, et al. Isolated minimal change nephropathy associated with diclofenac. Br Med J (Clin Res Ed) 1987; 295 (6591): 182-3 (Pubitemid 17101023)
13. Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs: evidence of a common mechanism. Br J Clin Pharmacol 1999; 47 (2): 203-10 (Pubitemid 29078020)
14. Perazella MA, Markowitz GS. Drug-induced acute interstitialnephritis. Nat Rev Nephrol 2010; 6 (8): 461-70
15. Mathieson PW. Minimal change nephropathy and focal segmental glomerulosclerosis. Semin Immunopathol 2007; 29 (4): 415-26 (Pubitemid 350077265)
16. Cornejo-Garcia JA, Blanca-Lopez N, Dona I, et al. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Curr Drug Metab 2009; 10 (9): 971-80
17. Rocha JL, FernandezAlonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme in-hibitor, rofecoxib. Lancet 2001; 357 (9272): 1946-7 (Pubitemid 32568339)
18. Alim N, Peterson L, Zimmerman SW, et al. Rofecoxibinduced acute interstitial nephritis. Am J Kidney Dis 2003; 41 (3): 720-1
19. Quiralte J, Blanco C, Delgado J, et al. Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced- reactions. J Investig Al-lergol Clin Immunol 2007; 17 (3): 182-8 (Pubitemid 46890116)
20. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Tolerance ofnonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 2005; 94 (1): 34-8 (Pubitemid 40129632)
21. Senna G, Bilo MB, Antonicelli L, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, cele-coxib and rofecoxib in NSAID-sensitive patients. Eur Ann Allergy Clin Immunol 2004; 36 (6): 215-8 (Pubitemid 38915640)
22. Viola M, Quaratino D, Gaeta F, et al. Cross-reactive reactions to nonsteroidal anti-inflammatory drugs. Curr Pharm Des 2008; 14 (27): 2826-32
23. Weberschock TB, Muller SM, Boehncke S, et al. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature. Arch Dermatol Res 2007; 299 (4): 169-75 (Pubitemid 46955882)